Revenue
No reported data
| 2025 | 2024 | 2023 | 2022 |
|---|
Reported ownership
Verici Dx ($VRCI) announced plans for a further equity fundraising alongside first-half results showing revenue of approximately $1.8 million, versus $1.9 million previously. Tutivia testing revenue increased 53% to $1.77 million, but the p ...
Verici Dx ($VRCI) plans to launch TranscripTx in the fourth quarter as a genetic test designed specifically for organ-transplant recipients. The test uses next-generation sequencing of peripheral-blood RNA to identify variants that may info ...